Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antiviral Agents | 137 | 2019 | 510 | 15.840 |
Why?
|
Herpes Simplex | 122 | 2024 | 202 | 13.150 |
Why?
|
Simplexvirus | 83 | 2022 | 151 | 8.670 |
Why?
|
Herpes Zoster | 55 | 2014 | 78 | 6.610 |
Why?
|
Acyclovir | 74 | 2015 | 107 | 5.590 |
Why?
|
Herpes Genitalis | 33 | 2022 | 41 | 5.300 |
Why?
|
Herpesvirus 1, Human | 32 | 2022 | 244 | 4.600 |
Why?
|
Herpesvirus 2, Human | 24 | 2024 | 45 | 4.530 |
Why?
|
Influenza, Human | 21 | 2016 | 329 | 4.010 |
Why?
|
Cytomegalovirus Infections | 43 | 2019 | 144 | 3.930 |
Why?
|
Encephalitis | 54 | 2015 | 104 | 2.810 |
Why?
|
Oseltamivir | 11 | 2016 | 20 | 2.520 |
Why?
|
Herpesviridae Infections | 31 | 2009 | 46 | 2.330 |
Why?
|
Vidarabine | 53 | 2005 | 141 | 2.320 |
Why?
|
Pregnancy Complications, Infectious | 27 | 2024 | 105 | 2.290 |
Why?
|
Virus Shedding | 10 | 2022 | 26 | 2.280 |
Why?
|
Chickenpox | 25 | 2012 | 39 | 2.210 |
Why?
|
Encephalitis, Herpes Simplex | 9 | 2015 | 16 | 2.130 |
Why?
|
Infant, Newborn, Diseases | 20 | 2019 | 111 | 1.960 |
Why?
|
Infant, Newborn | 87 | 2024 | 2379 | 1.720 |
Why?
|
Ganciclovir | 18 | 2019 | 49 | 1.710 |
Why?
|
Humans | 360 | 2024 | 86643 | 1.690 |
Why?
|
Virus Diseases | 16 | 2016 | 97 | 1.650 |
Why?
|
Glioma | 15 | 2014 | 285 | 1.570 |
Why?
|
2-Aminopurine | 10 | 2011 | 11 | 1.510 |
Why?
|
Virus Replication | 33 | 2020 | 319 | 1.490 |
Why?
|
Drug Resistance, Viral | 11 | 2014 | 51 | 1.490 |
Why?
|
Interleukin-12 | 8 | 2014 | 108 | 1.400 |
Why?
|
Drug Discovery | 4 | 2016 | 103 | 1.390 |
Why?
|
Valine | 12 | 2015 | 69 | 1.300 |
Why?
|
Oncolytic Virotherapy | 7 | 2020 | 41 | 1.290 |
Why?
|
Infectious Disease Transmission, Vertical | 8 | 2024 | 44 | 1.270 |
Why?
|
Disease Outbreaks | 6 | 2008 | 154 | 1.250 |
Why?
|
Clinical Trials as Topic | 44 | 2019 | 1169 | 1.250 |
Why?
|
DNA, Viral | 21 | 2011 | 265 | 1.130 |
Why?
|
Herpesvirus 3, Human | 18 | 2011 | 43 | 1.090 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2016 | 865 | 1.070 |
Why?
|
Genetic Therapy | 14 | 2019 | 342 | 0.990 |
Why?
|
Genetic Vectors | 10 | 2019 | 439 | 0.990 |
Why?
|
Herpes Zoster Vaccine | 4 | 2014 | 10 | 0.980 |
Why?
|
Brain Neoplasms | 13 | 2019 | 763 | 0.970 |
Why?
|
Neuralgia, Postherpetic | 5 | 2010 | 5 | 0.950 |
Why?
|
Antibodies, Viral | 21 | 2019 | 293 | 0.920 |
Why?
|
AIDS-Related Opportunistic Infections | 6 | 2012 | 33 | 0.900 |
Why?
|
Herpesvirus 6, Human | 6 | 2009 | 19 | 0.890 |
Why?
|
Virus Activation | 7 | 2013 | 41 | 0.870 |
Why?
|
Fibromyalgia | 1 | 2022 | 14 | 0.850 |
Why?
|
Influenza A virus | 4 | 2014 | 169 | 0.840 |
Why?
|
Helicobacter Infections | 1 | 2022 | 34 | 0.840 |
Why?
|
Gastritis | 1 | 2022 | 32 | 0.830 |
Why?
|
Helicobacter pylori | 1 | 2022 | 35 | 0.830 |
Why?
|
Infant | 47 | 2015 | 3046 | 0.820 |
Why?
|
Female | 137 | 2024 | 44532 | 0.810 |
Why?
|
Child | 52 | 2020 | 6927 | 0.800 |
Why?
|
Pain Measurement | 4 | 2008 | 321 | 0.790 |
Why?
|
Disease Models, Animal | 13 | 2013 | 2232 | 0.780 |
Why?
|
Roseolovirus Infections | 2 | 2014 | 7 | 0.780 |
Why?
|
Genetic Engineering | 12 | 2013 | 114 | 0.770 |
Why?
|
Gastrointestinal Diseases | 1 | 2022 | 146 | 0.760 |
Why?
|
Cytomegalovirus | 18 | 2012 | 76 | 0.760 |
Why?
|
Encephalitis, Viral | 6 | 2019 | 7 | 0.750 |
Why?
|
Acquired Immunodeficiency Syndrome | 9 | 2007 | 78 | 0.740 |
Why?
|
Polymerase Chain Reaction | 17 | 2012 | 927 | 0.740 |
Why?
|
Viral Vaccines | 10 | 2002 | 43 | 0.720 |
Why?
|
Central Nervous System Viral Diseases | 4 | 2019 | 4 | 0.720 |
Why?
|
Recurrence | 27 | 2016 | 1139 | 0.710 |
Why?
|
Pain | 9 | 2002 | 391 | 0.690 |
Why?
|
Viruses | 3 | 2016 | 78 | 0.670 |
Why?
|
Organophosphonates | 6 | 1998 | 50 | 0.670 |
Why?
|
HIV Infections | 13 | 2010 | 772 | 0.670 |
Why?
|
Herpes Labialis | 7 | 2011 | 9 | 0.670 |
Why?
|
Adult | 90 | 2019 | 25648 | 0.660 |
Why?
|
Virus Latency | 4 | 2013 | 33 | 0.640 |
Why?
|
Influenza A Virus, H1N1 Subtype | 3 | 2010 | 102 | 0.640 |
Why?
|
Meningitis, Viral | 3 | 2006 | 10 | 0.640 |
Why?
|
Animals | 65 | 2018 | 26582 | 0.620 |
Why?
|
Central Nervous System Diseases | 10 | 2011 | 52 | 0.620 |
Why?
|
Male | 109 | 2020 | 40965 | 0.620 |
Why?
|
Enterovirus Infections | 6 | 2015 | 41 | 0.600 |
Why?
|
Pregnancy | 31 | 2024 | 2894 | 0.590 |
Why?
|
Health Planning | 2 | 2006 | 17 | 0.590 |
Why?
|
Child, Preschool | 28 | 2020 | 3612 | 0.570 |
Why?
|
Viral Load | 10 | 2015 | 148 | 0.540 |
Why?
|
Ribavirin | 3 | 2011 | 57 | 0.540 |
Why?
|
Antibodies, Monoclonal | 13 | 2009 | 1376 | 0.530 |
Why?
|
Immunocompromised Host | 8 | 2014 | 140 | 0.530 |
Why?
|
Treatment Outcome | 23 | 2019 | 7993 | 0.520 |
Why?
|
Neuraminidase | 2 | 2013 | 45 | 0.520 |
Why?
|
Influenza A Virus, H5N1 Subtype | 3 | 2010 | 63 | 0.520 |
Why?
|
Guanidines | 1 | 2014 | 31 | 0.510 |
Why?
|
Drug Delivery Systems | 1 | 2016 | 178 | 0.510 |
Why?
|
Cyclopentanes | 1 | 2014 | 27 | 0.510 |
Why?
|
Herpes Simplex Virus Vaccines | 3 | 2018 | 5 | 0.500 |
Why?
|
Adolescent | 41 | 2020 | 8981 | 0.490 |
Why?
|
Disease Management | 2 | 2018 | 327 | 0.480 |
Why?
|
Arabinofuranosyluracil | 4 | 1998 | 6 | 0.480 |
Why?
|
Viral Envelope Proteins | 13 | 1998 | 94 | 0.480 |
Why?
|
Influenza Vaccines | 4 | 2008 | 142 | 0.480 |
Why?
|
Prednisone | 5 | 1999 | 258 | 0.470 |
Why?
|
Administration, Oral | 15 | 2014 | 684 | 0.470 |
Why?
|
Glioblastoma | 2 | 2013 | 255 | 0.460 |
Why?
|
Oxadiazoles | 3 | 2015 | 46 | 0.460 |
Why?
|
Viral Proteins | 15 | 2024 | 300 | 0.460 |
Why?
|
Vaccination | 5 | 2006 | 254 | 0.460 |
Why?
|
Thiazoles | 1 | 2014 | 131 | 0.450 |
Why?
|
Neuralgia | 5 | 2002 | 28 | 0.450 |
Why?
|
Double-Blind Method | 27 | 2015 | 1823 | 0.440 |
Why?
|
Chickenpox Vaccine | 3 | 2009 | 7 | 0.430 |
Why?
|
Immunotherapy | 5 | 2019 | 629 | 0.430 |
Why?
|
Encephalitis, California | 1 | 2011 | 2 | 0.420 |
Why?
|
Middle Aged | 56 | 2019 | 25028 | 0.420 |
Why?
|
Respiratory Syncytial Viruses | 4 | 2015 | 14 | 0.410 |
Why?
|
Pyridines | 1 | 2014 | 310 | 0.410 |
Why?
|
Academies and Institutes | 1 | 2011 | 31 | 0.390 |
Why?
|
Guanine | 8 | 1999 | 208 | 0.390 |
Why?
|
Time Factors | 29 | 2015 | 5210 | 0.380 |
Why?
|
United States | 21 | 2014 | 6672 | 0.380 |
Why?
|
Anti-Infective Agents | 7 | 2008 | 89 | 0.380 |
Why?
|
West Nile Fever | 3 | 2019 | 21 | 0.370 |
Why?
|
Ferrets | 1 | 2010 | 47 | 0.370 |
Why?
|
Universities | 1 | 2011 | 135 | 0.370 |
Why?
|
Aged | 35 | 2019 | 18415 | 0.370 |
Why?
|
Orthomyxoviridae Infections | 1 | 2010 | 46 | 0.370 |
Why?
|
Conflict of Interest | 2 | 2010 | 67 | 0.360 |
Why?
|
Central Nervous System Neoplasms | 2 | 2001 | 81 | 0.350 |
Why?
|
Hearing Loss, Sensorineural | 3 | 2019 | 46 | 0.350 |
Why?
|
Hearing Loss, Central | 1 | 2009 | 3 | 0.350 |
Why?
|
Disclosure | 1 | 2010 | 108 | 0.340 |
Why?
|
Antirheumatic Agents | 1 | 2009 | 54 | 0.330 |
Why?
|
Vaccines, Synthetic | 4 | 2005 | 55 | 0.330 |
Why?
|
Respiratory Syncytial Virus Infections | 3 | 2015 | 23 | 0.330 |
Why?
|
Keratitis, Dendritic | 9 | 1988 | 13 | 0.330 |
Why?
|
Arenavirus | 1 | 2008 | 1 | 0.320 |
Why?
|
Arenaviridae Infections | 1 | 2008 | 4 | 0.320 |
Why?
|
Oncolytic Viruses | 4 | 2019 | 23 | 0.320 |
Why?
|
Antigens, Viral | 12 | 1996 | 143 | 0.320 |
Why?
|
Hepatitis B | 4 | 2004 | 74 | 0.310 |
Why?
|
Brain | 23 | 2012 | 2216 | 0.310 |
Why?
|
HIV Seropositivity | 3 | 2012 | 49 | 0.300 |
Why?
|
Neonatal Screening | 1 | 2008 | 59 | 0.300 |
Why?
|
Technology, Pharmaceutical | 1 | 2007 | 30 | 0.300 |
Why?
|
Government Programs | 1 | 2006 | 8 | 0.300 |
Why?
|
Meningitis, Bacterial | 3 | 2004 | 13 | 0.300 |
Why?
|
Incidence | 8 | 2009 | 1577 | 0.290 |
Why?
|
Genes, Viral | 6 | 2013 | 116 | 0.290 |
Why?
|
Microbial Sensitivity Tests | 4 | 2014 | 143 | 0.290 |
Why?
|
Drug Resistance, Microbial | 9 | 1996 | 72 | 0.290 |
Why?
|
Headache | 2 | 2006 | 73 | 0.290 |
Why?
|
Immunization, Passive | 4 | 1994 | 71 | 0.290 |
Why?
|
Interferon Type I | 7 | 1999 | 175 | 0.280 |
Why?
|
Clinical Trials Data Monitoring Committees | 2 | 2004 | 6 | 0.280 |
Why?
|
HIV-1 | 8 | 2012 | 163 | 0.280 |
Why?
|
Mice | 28 | 2014 | 11352 | 0.280 |
Why?
|
Seasons | 5 | 2014 | 223 | 0.270 |
Why?
|
Disease Transmission, Infectious | 3 | 2016 | 57 | 0.260 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 112 | 0.260 |
Why?
|
Prevalence | 6 | 2022 | 1239 | 0.260 |
Why?
|
Drug Administration Schedule | 11 | 2015 | 916 | 0.260 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2009 | 683 | 0.260 |
Why?
|
Proportional Hazards Models | 4 | 2002 | 859 | 0.260 |
Why?
|
Condylomata Acuminata | 4 | 1988 | 15 | 0.260 |
Why?
|
Diphosphates | 2 | 2008 | 18 | 0.250 |
Why?
|
Central Nervous System | 6 | 2010 | 151 | 0.250 |
Why?
|
Hepatitis B virus | 1 | 2004 | 43 | 0.250 |
Why?
|
Sequence Analysis, DNA | 1 | 2008 | 853 | 0.250 |
Why?
|
Organophosphorus Compounds | 5 | 1998 | 55 | 0.250 |
Why?
|
HIV | 1 | 2004 | 46 | 0.250 |
Why?
|
Hepacivirus | 2 | 2005 | 159 | 0.240 |
Why?
|
Smallpox | 2 | 2003 | 6 | 0.240 |
Why?
|
Cytosine | 5 | 1998 | 127 | 0.240 |
Why?
|
Analgesics | 3 | 2010 | 119 | 0.230 |
Why?
|
United States Food and Drug Administration | 1 | 2004 | 127 | 0.230 |
Why?
|
Variola virus | 1 | 2003 | 1 | 0.230 |
Why?
|
Anti-Inflammatory Agents | 3 | 2007 | 339 | 0.230 |
Why?
|
Biological Warfare | 1 | 2003 | 6 | 0.230 |
Why?
|
Smallpox Vaccine | 1 | 2003 | 12 | 0.230 |
Why?
|
Bioterrorism | 1 | 2003 | 18 | 0.220 |
Why?
|
Drug Evaluation | 14 | 1996 | 141 | 0.220 |
Why?
|
Hepatitis C | 2 | 2004 | 208 | 0.220 |
Why?
|
Anti-HIV Agents | 4 | 1999 | 149 | 0.220 |
Why?
|
Risk Factors | 11 | 2012 | 5417 | 0.220 |
Why?
|
Mice, SCID | 5 | 2012 | 252 | 0.220 |
Why?
|
Cross Infection | 4 | 2010 | 141 | 0.220 |
Why?
|
Cytomegalovirus Retinitis | 2 | 1999 | 7 | 0.220 |
Why?
|
Research Design | 9 | 1997 | 594 | 0.220 |
Why?
|
Enterovirus | 3 | 2015 | 34 | 0.210 |
Why?
|
Glycoproteins | 7 | 1988 | 234 | 0.210 |
Why?
|
West Nile virus | 2 | 2019 | 16 | 0.210 |
Why?
|
Age Factors | 11 | 2014 | 1851 | 0.210 |
Why?
|
Respiratory Tract Infections | 5 | 2006 | 105 | 0.210 |
Why?
|
Sulfonamides | 2 | 2014 | 300 | 0.210 |
Why?
|
Immunocompetence | 3 | 2009 | 27 | 0.210 |
Why?
|
Nervous System Diseases | 5 | 2014 | 151 | 0.210 |
Why?
|
Cell Line | 11 | 2019 | 2468 | 0.210 |
Why?
|
Practice Guidelines as Topic | 4 | 2016 | 1036 | 0.200 |
Why?
|
Killer Cells, Natural | 6 | 1990 | 267 | 0.200 |
Why?
|
Acetamides | 1 | 2001 | 26 | 0.200 |
Why?
|
Glucocorticoids | 2 | 2009 | 352 | 0.190 |
Why?
|
Vaccines, Attenuated | 5 | 2005 | 51 | 0.190 |
Why?
|
Likelihood Functions | 1 | 2001 | 251 | 0.190 |
Why?
|
RNA, Viral | 3 | 2013 | 327 | 0.190 |
Why?
|
Cerebellar Neoplasms | 1 | 2020 | 36 | 0.190 |
Why?
|
Immune Tolerance | 6 | 1990 | 337 | 0.190 |
Why?
|
Immunologic Deficiency Syndromes | 3 | 1991 | 47 | 0.190 |
Why?
|
Biopsy | 14 | 1991 | 1163 | 0.190 |
Why?
|
Foscarnet | 2 | 1998 | 12 | 0.180 |
Why?
|
Temporal Lobe | 2 | 2015 | 172 | 0.180 |
Why?
|
Immunoglobulin G | 3 | 2019 | 456 | 0.180 |
Why?
|
Injections, Intravenous | 9 | 2009 | 244 | 0.180 |
Why?
|
Intussusception | 1 | 1999 | 16 | 0.180 |
Why?
|
Rotavirus Infections | 1 | 1999 | 12 | 0.180 |
Why?
|
Data Interpretation, Statistical | 1 | 2001 | 297 | 0.180 |
Why?
|
Pneumonia, Viral | 7 | 2006 | 316 | 0.180 |
Why?
|
Therapies, Investigational | 1 | 2019 | 17 | 0.180 |
Why?
|
Cooperative Behavior | 2 | 2011 | 174 | 0.180 |
Why?
|
Genetic Variation | 4 | 2019 | 1351 | 0.170 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2019 | 66 | 0.170 |
Why?
|
Herpesvirus 7, Human | 1 | 1998 | 3 | 0.170 |
Why?
|
Eye Infections, Viral | 2 | 1996 | 5 | 0.170 |
Why?
|
Infusions, Intravenous | 6 | 2011 | 429 | 0.170 |
Why?
|
Ribonucleosides | 1 | 1998 | 25 | 0.170 |
Why?
|
Virulence | 4 | 2006 | 271 | 0.170 |
Why?
|
Gene Editing | 1 | 2018 | 42 | 0.160 |
Why?
|
Acute Disease | 4 | 2014 | 826 | 0.160 |
Why?
|
Radiotherapy | 1 | 2020 | 328 | 0.160 |
Why?
|
Survival Analysis | 4 | 2012 | 1538 | 0.160 |
Why?
|
Sexual Behavior | 3 | 2012 | 302 | 0.160 |
Why?
|
Drug Therapy, Combination | 7 | 2015 | 894 | 0.160 |
Why?
|
Administration, Topical | 5 | 2011 | 95 | 0.150 |
Why?
|
Influenza in Birds | 2 | 2008 | 31 | 0.150 |
Why?
|
Fetal Diseases | 4 | 1989 | 81 | 0.150 |
Why?
|
Case-Control Studies | 1 | 2022 | 1805 | 0.150 |
Why?
|
Alphaherpesvirinae | 1 | 1997 | 1 | 0.150 |
Why?
|
Interleukins | 1 | 1998 | 134 | 0.150 |
Why?
|
Regression Analysis | 6 | 2014 | 596 | 0.150 |
Why?
|
Disease Progression | 5 | 2006 | 1531 | 0.150 |
Why?
|
Multivariate Analysis | 6 | 2015 | 999 | 0.150 |
Why?
|
Mouth Diseases | 2 | 1996 | 15 | 0.150 |
Why?
|
Orthomyxoviridae | 2 | 2012 | 37 | 0.150 |
Why?
|
Prospective Studies | 12 | 2014 | 4213 | 0.140 |
Why?
|
Alabama | 3 | 2011 | 13 | 0.140 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 592 | 0.140 |
Why?
|
Gestational Age | 4 | 2019 | 311 | 0.140 |
Why?
|
Skin Diseases, Viral | 1 | 1996 | 3 | 0.140 |
Why?
|
Multicenter Studies as Topic | 2 | 2014 | 159 | 0.140 |
Why?
|
Young Adult | 5 | 2015 | 5976 | 0.140 |
Why?
|
Models, Statistical | 3 | 2015 | 574 | 0.140 |
Why?
|
Prenatal Care | 2 | 2007 | 72 | 0.140 |
Why?
|
Aotidae | 2 | 2014 | 7 | 0.140 |
Why?
|
Primary Prevention | 2 | 2006 | 85 | 0.140 |
Why?
|
High-Throughput Screening Assays | 1 | 2016 | 55 | 0.140 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2016 | 59 | 0.140 |
Why?
|
Neonatal Sepsis | 1 | 2015 | 3 | 0.130 |
Why?
|
Gene Expression | 4 | 2012 | 1284 | 0.130 |
Why?
|
Immediate-Early Proteins | 3 | 1997 | 164 | 0.130 |
Why?
|
Retrospective Studies | 9 | 2015 | 8489 | 0.130 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2015 | 78 | 0.130 |
Why?
|
Seizures | 4 | 1998 | 297 | 0.130 |
Why?
|
Acids, Carbocyclic | 1 | 2014 | 1 | 0.130 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2014 | 24 | 0.130 |
Why?
|
Inhibitory Concentration 50 | 1 | 2014 | 64 | 0.130 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2014 | 17 | 0.130 |
Why?
|
Drug Dosage Calculations | 1 | 2014 | 16 | 0.120 |
Why?
|
Cells, Cultured | 11 | 2015 | 2818 | 0.120 |
Why?
|
Mouth | 3 | 2005 | 48 | 0.120 |
Why?
|
Organ Transplantation | 2 | 2008 | 265 | 0.120 |
Why?
|
Receptors, Virus | 1 | 2014 | 74 | 0.120 |
Why?
|
Newspapers as Topic | 1 | 2014 | 6 | 0.120 |
Why?
|
Infusions, Intraventricular | 1 | 2014 | 5 | 0.120 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 7 | 2012 | 376 | 0.120 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2014 | 15 | 0.120 |
Why?
|
History, 20th Century | 5 | 2004 | 312 | 0.120 |
Why?
|
Interleukin-15 Receptor alpha Subunit | 1 | 2013 | 6 | 0.120 |
Why?
|
Genome, Viral | 3 | 2019 | 74 | 0.120 |
Why?
|
Aged, 80 and over | 5 | 2015 | 6509 | 0.120 |
Why?
|
Oxazoles | 3 | 2015 | 19 | 0.120 |
Why?
|
Stomatitis, Herpetic | 4 | 1986 | 5 | 0.120 |
Why?
|
Neuroimaging | 1 | 2015 | 113 | 0.120 |
Why?
|
Infertility | 1 | 2014 | 37 | 0.120 |
Why?
|
Eye | 3 | 2005 | 111 | 0.120 |
Why?
|
Severity of Illness Index | 6 | 2014 | 1801 | 0.120 |
Why?
|
Cell Adhesion Molecules | 1 | 2014 | 163 | 0.120 |
Why?
|
Child Development | 2 | 2015 | 163 | 0.120 |
Why?
|
Arabinonucleotides | 2 | 1985 | 3 | 0.120 |
Why?
|
Vidarabine Phosphate | 2 | 1985 | 5 | 0.120 |
Why?
|
Base Sequence | 8 | 1998 | 2330 | 0.120 |
Why?
|
Mice, Inbred BALB C | 4 | 2009 | 1047 | 0.120 |
Why?
|
Managed Care Programs | 2 | 2007 | 42 | 0.110 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2013 | 24 | 0.110 |
Why?
|
Pyrazoles | 1 | 2014 | 153 | 0.110 |
Why?
|
Cell Fusion | 3 | 1989 | 39 | 0.110 |
Why?
|
Interleukin-15 | 1 | 2013 | 72 | 0.110 |
Why?
|
Information Dissemination | 1 | 2014 | 103 | 0.110 |
Why?
|
Clinical Protocols | 5 | 2006 | 156 | 0.110 |
Why?
|
Host-Pathogen Interactions | 1 | 2015 | 231 | 0.110 |
Why?
|
Neutropenia | 2 | 2015 | 215 | 0.110 |
Why?
|
Vaccines, Inactivated | 3 | 2002 | 29 | 0.110 |
Why?
|
Molecular Sequence Data | 8 | 1998 | 3030 | 0.110 |
Why?
|
Quality-Adjusted Life Years | 2 | 2007 | 138 | 0.110 |
Why?
|
Drug Users | 1 | 2012 | 19 | 0.110 |
Why?
|
Interferons | 5 | 1994 | 133 | 0.110 |
Why?
|
Kidney Transplantation | 7 | 2012 | 849 | 0.110 |
Why?
|
Quality of Life | 5 | 2015 | 1585 | 0.110 |
Why?
|
Viral Matrix Proteins | 1 | 2012 | 14 | 0.110 |
Why?
|
Students, Dental | 1 | 1992 | 4 | 0.110 |
Why?
|
Vero Cells | 6 | 2006 | 100 | 0.110 |
Why?
|
La Crosse virus | 1 | 2011 | 2 | 0.100 |
Why?
|
Anticonvulsants | 2 | 2010 | 126 | 0.100 |
Why?
|
Follow-Up Studies | 13 | 2015 | 3640 | 0.100 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2012 | 104 | 0.100 |
Why?
|
Prognosis | 7 | 2014 | 3679 | 0.100 |
Why?
|
Prodrugs | 3 | 1999 | 46 | 0.100 |
Why?
|
Neoplasms | 9 | 2005 | 2898 | 0.100 |
Why?
|
Global Health | 2 | 2006 | 193 | 0.100 |
Why?
|
Random Allocation | 8 | 1999 | 332 | 0.100 |
Why?
|
Nonprescription Drugs | 1 | 2011 | 15 | 0.100 |
Why?
|
Clinical Trials, Phase I as Topic | 6 | 2020 | 155 | 0.100 |
Why?
|
Renal Insufficiency | 1 | 2012 | 114 | 0.100 |
Why?
|
Drug Interactions | 1 | 2012 | 248 | 0.100 |
Why?
|
Algorithms | 2 | 2013 | 1830 | 0.100 |
Why?
|
Prescription Drugs | 1 | 2011 | 36 | 0.100 |
Why?
|
Tunicamycin | 2 | 1990 | 12 | 0.100 |
Why?
|
Forecasting | 3 | 1997 | 304 | 0.100 |
Why?
|
Cancer Vaccines | 2 | 2005 | 156 | 0.100 |
Why?
|
Sensitivity and Specificity | 4 | 2007 | 1991 | 0.100 |
Why?
|
Societies | 1 | 2010 | 12 | 0.100 |
Why?
|
Phosphoproteins | 1 | 2012 | 254 | 0.100 |
Why?
|
Meningoencephalitis | 4 | 1998 | 10 | 0.100 |
Why?
|
Genomics | 2 | 2019 | 720 | 0.100 |
Why?
|
Rabbits | 7 | 1993 | 636 | 0.100 |
Why?
|
Reference Values | 2 | 2003 | 674 | 0.100 |
Why?
|
Diagnosis, Differential | 9 | 2015 | 1565 | 0.090 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2010 | 19 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2012 | 458 | 0.090 |
Why?
|
Rimantadine | 1 | 2010 | 9 | 0.090 |
Why?
|
Adamantane | 1 | 2010 | 8 | 0.090 |
Why?
|
Transplantation, Heterologous | 4 | 2006 | 363 | 0.090 |
Why?
|
Fluorescent Antibody Technique | 9 | 1993 | 316 | 0.090 |
Why?
|
Financial Support | 1 | 2010 | 7 | 0.090 |
Why?
|
Circumcision, Male | 1 | 2010 | 18 | 0.090 |
Why?
|
Guanosine Triphosphate | 1 | 1990 | 38 | 0.090 |
Why?
|
Pyrimidine Nucleosides | 1 | 2009 | 6 | 0.090 |
Why?
|
Herpesviridae | 1 | 2009 | 14 | 0.090 |
Why?
|
Cytotoxicity, Immunologic | 2 | 1990 | 213 | 0.090 |
Why?
|
Neuroblastoma | 2 | 2006 | 374 | 0.090 |
Why?
|
Herpes Zoster Oticus | 1 | 2009 | 2 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2007 | 1961 | 0.090 |
Why?
|
Infection Control | 1 | 2010 | 115 | 0.090 |
Why?
|
Drug Industry | 1 | 2010 | 54 | 0.090 |
Why?
|
Sexually Transmitted Diseases | 2 | 1988 | 91 | 0.090 |
Why?
|
Trigeminal Nerve | 4 | 1993 | 18 | 0.090 |
Why?
|
Fever | 5 | 1999 | 125 | 0.090 |
Why?
|
Adrenal Cortex Hormones | 2 | 2002 | 263 | 0.090 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 199 | 0.090 |
Why?
|
Viremia | 2 | 2004 | 54 | 0.090 |
Why?
|
Risk | 4 | 2006 | 674 | 0.080 |
Why?
|
Gene Products, gag | 2 | 2007 | 12 | 0.080 |
Why?
|
Chronic Disease | 3 | 2001 | 971 | 0.080 |
Why?
|
Publishing | 1 | 2010 | 90 | 0.080 |
Why?
|
Gene Expression Regulation, Viral | 2 | 2007 | 90 | 0.080 |
Why?
|
Isoelectric Focusing | 1 | 1988 | 39 | 0.080 |
Why?
|
History, 19th Century | 3 | 2001 | 59 | 0.080 |
Why?
|
Genital Neoplasms, Male | 2 | 1988 | 11 | 0.080 |
Why?
|
Risk Assessment | 4 | 2011 | 2261 | 0.080 |
Why?
|
Models, Biological | 2 | 2014 | 1749 | 0.080 |
Why?
|
Middle East | 1 | 2008 | 17 | 0.080 |
Why?
|
Liver Failure, Acute | 1 | 2008 | 38 | 0.080 |
Why?
|
Cryptococcosis | 1 | 1988 | 11 | 0.080 |
Why?
|
Asia | 1 | 2008 | 95 | 0.080 |
Why?
|
Osteomyelitis | 1 | 1988 | 54 | 0.080 |
Why?
|
Idoxuridine | 7 | 1985 | 16 | 0.080 |
Why?
|
Biomarkers | 2 | 2004 | 1718 | 0.080 |
Why?
|
Drug and Narcotic Control | 1 | 2007 | 7 | 0.080 |
Why?
|
Communicable Disease Control | 1 | 2008 | 51 | 0.080 |
Why?
|
Developmental Disabilities | 1 | 2009 | 195 | 0.080 |
Why?
|
DNA Restriction Enzymes | 3 | 1987 | 98 | 0.080 |
Why?
|
Diagnosis-Related Groups | 1 | 2007 | 20 | 0.080 |
Why?
|
Sweden | 1 | 2007 | 40 | 0.080 |
Why?
|
Membrane Glycoproteins | 1 | 1990 | 428 | 0.080 |
Why?
|
Interleukin-2 | 2 | 1990 | 249 | 0.080 |
Why?
|
Placebos | 5 | 2004 | 218 | 0.080 |
Why?
|
Combined Modality Therapy | 5 | 2020 | 1686 | 0.080 |
Why?
|
Anesthetics | 1 | 2008 | 48 | 0.080 |
Why?
|
History, 18th Century | 2 | 2001 | 23 | 0.080 |
Why?
|
Arthritis, Rheumatoid | 1 | 2009 | 166 | 0.080 |
Why?
|
Arabinonucleosides | 2 | 1985 | 39 | 0.080 |
Why?
|
Genital Neoplasms, Female | 2 | 1988 | 107 | 0.070 |
Why?
|
Zanamivir | 1 | 2006 | 2 | 0.070 |
Why?
|
Bromodeoxyuridine | 1 | 2007 | 57 | 0.070 |
Why?
|
Poultry | 1 | 2006 | 22 | 0.070 |
Why?
|
Medical Records | 1 | 2007 | 119 | 0.070 |
Why?
|
Cytosine Deaminase | 1 | 2006 | 9 | 0.070 |
Why?
|
Leukemia | 2 | 2006 | 320 | 0.070 |
Why?
|
Financial Management | 1 | 2006 | 21 | 0.070 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2006 | 70 | 0.070 |
Why?
|
Herpes Zoster Ophthalmicus | 2 | 2002 | 6 | 0.070 |
Why?
|
Homes for the Aged | 1 | 2006 | 26 | 0.070 |
Why?
|
Blood Transfusion | 1 | 1987 | 157 | 0.070 |
Why?
|
Genital Diseases, Male | 1 | 2006 | 8 | 0.070 |
Why?
|
Birds | 1 | 2008 | 157 | 0.070 |
Why?
|
Neuritis | 2 | 1999 | 8 | 0.070 |
Why?
|
Viral Interference | 1 | 1985 | 4 | 0.070 |
Why?
|
Neoplasm Transplantation | 4 | 2005 | 391 | 0.070 |
Why?
|
Mass Screening | 2 | 2012 | 618 | 0.070 |
Why?
|
Parvoviridae Infections | 1 | 1985 | 6 | 0.070 |
Why?
|
Trigeminal Ganglion | 1 | 2005 | 16 | 0.070 |
Why?
|
Hepatitis, Viral, Human | 2 | 1998 | 25 | 0.070 |
Why?
|
Cognition | 1 | 1990 | 570 | 0.070 |
Why?
|
Area Under Curve | 3 | 2014 | 334 | 0.070 |
Why?
|
Evolution, Molecular | 1 | 2011 | 813 | 0.070 |
Why?
|
Interferon-gamma | 1 | 1987 | 444 | 0.070 |
Why?
|
Chemokine CCL2 | 1 | 2005 | 47 | 0.070 |
Why?
|
Nursing Homes | 1 | 2006 | 109 | 0.060 |
Why?
|
Infant, Premature | 3 | 2010 | 290 | 0.060 |
Why?
|
Hantavirus Pulmonary Syndrome | 1 | 2004 | 1 | 0.060 |
Why?
|
Retinitis | 2 | 1998 | 3 | 0.060 |
Why?
|
Genetic Markers | 1 | 1986 | 476 | 0.060 |
Why?
|
Patient Compliance | 1 | 2006 | 227 | 0.060 |
Why?
|
Bacterial Infections | 2 | 1984 | 182 | 0.060 |
Why?
|
Aspartate Aminotransferases | 3 | 2001 | 73 | 0.060 |
Why?
|
Immunoglobulins | 1 | 2005 | 148 | 0.060 |
Why?
|
Computational Biology | 1 | 2008 | 528 | 0.060 |
Why?
|
CD4 Lymphocyte Count | 1 | 2004 | 66 | 0.060 |
Why?
|
Cell Line, Tumor | 4 | 2014 | 2426 | 0.060 |
Why?
|
Cerebrospinal Fluid Shunts | 1 | 2004 | 48 | 0.060 |
Why?
|
Hearing Loss | 1 | 2004 | 56 | 0.060 |
Why?
|
Interferon Inducers | 1 | 1984 | 3 | 0.060 |
Why?
|
Tropism | 1 | 2024 | 4 | 0.060 |
Why?
|
Skin Diseases, Infectious | 4 | 1992 | 13 | 0.060 |
Why?
|
Recombinant Proteins | 6 | 1999 | 1014 | 0.060 |
Why?
|
Hepatitis C, Chronic | 1 | 2005 | 126 | 0.060 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2004 | 64 | 0.060 |
Why?
|
Psychotic Disorders | 1 | 1985 | 184 | 0.060 |
Why?
|
Secondary Prevention | 3 | 2011 | 162 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 2 | 2015 | 3362 | 0.060 |
Why?
|
Chlamydia Infections | 3 | 2012 | 25 | 0.060 |
Why?
|
Consciousness | 3 | 1991 | 26 | 0.060 |
Why?
|
Drug Therapy | 1 | 2004 | 70 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2006 | 639 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 4 | 2012 | 425 | 0.060 |
Why?
|
Research Support as Topic | 1 | 2004 | 80 | 0.060 |
Why?
|
Cerebrospinal Fluid | 3 | 1998 | 32 | 0.060 |
Why?
|
Tumor Cells, Cultured | 6 | 2006 | 1041 | 0.060 |
Why?
|
Cytopathogenic Effect, Viral | 2 | 2006 | 7 | 0.060 |
Why?
|
Immunity, Cellular | 5 | 1992 | 177 | 0.060 |
Why?
|
Safety | 2 | 2001 | 152 | 0.060 |
Why?
|
Convalescence | 2 | 2001 | 12 | 0.060 |
Why?
|
Patient Satisfaction | 1 | 2006 | 455 | 0.060 |
Why?
|
Communication | 1 | 2006 | 441 | 0.060 |
Why?
|
Aging | 2 | 2007 | 691 | 0.060 |
Why?
|
DNA-Directed DNA Polymerase | 2 | 2009 | 25 | 0.060 |
Why?
|
Purine Nucleosides | 4 | 1976 | 7 | 0.060 |
Why?
|
Leukocyte Count | 4 | 1997 | 220 | 0.050 |
Why?
|
Bacteria | 1 | 2006 | 447 | 0.050 |
Why?
|
Immunoblotting | 4 | 1991 | 268 | 0.050 |
Why?
|
Mothers | 1 | 2024 | 141 | 0.050 |
Why?
|
Protein Kinases | 1 | 2024 | 209 | 0.050 |
Why?
|
Guidelines as Topic | 1 | 2004 | 162 | 0.050 |
Why?
|
Kinetics | 6 | 1983 | 1513 | 0.050 |
Why?
|
Drug Implants | 2 | 1999 | 34 | 0.050 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 1988 | 567 | 0.050 |
Why?
|
Cost-Benefit Analysis | 2 | 1997 | 454 | 0.050 |
Why?
|
Kidney | 5 | 1992 | 1241 | 0.050 |
Why?
|
Transplantation, Isogeneic | 2 | 2005 | 39 | 0.050 |
Why?
|
Arboviruses | 1 | 2002 | 3 | 0.050 |
Why?
|
Vaccines, Subunit | 1 | 2002 | 55 | 0.050 |
Why?
|
Mutation | 3 | 2024 | 3968 | 0.050 |
Why?
|
Splenomegaly | 2 | 2003 | 27 | 0.050 |
Why?
|
Hepatomegaly | 2 | 2003 | 15 | 0.050 |
Why?
|
Anti-Bacterial Agents | 2 | 2004 | 746 | 0.050 |
Why?
|
Proteomics | 1 | 2024 | 212 | 0.050 |
Why?
|
Liver Neoplasms, Experimental | 1 | 2002 | 27 | 0.050 |
Why?
|
Hepatitis B Vaccines | 1 | 2001 | 13 | 0.050 |
Why?
|
T-Lymphocytes | 6 | 1989 | 1195 | 0.050 |
Why?
|
Effect Modifier, Epidemiologic | 1 | 2001 | 5 | 0.050 |
Why?
|
Toxoplasmosis, Congenital | 1 | 1981 | 42 | 0.050 |
Why?
|
History, Medieval | 1 | 2001 | 11 | 0.050 |
Why?
|
Chorioretinitis | 2 | 1993 | 10 | 0.050 |
Why?
|
Skin | 3 | 1996 | 554 | 0.050 |
Why?
|
Evidence-Based Medicine | 3 | 2008 | 429 | 0.050 |
Why?
|
History, Ancient | 1 | 2001 | 74 | 0.050 |
Why?
|
Immunohistochemistry | 3 | 2005 | 1753 | 0.050 |
Why?
|
Bias | 1 | 2001 | 127 | 0.050 |
Why?
|
Encephalomyelitis, Equine | 1 | 1980 | 1 | 0.050 |
Why?
|
Cough | 1 | 2001 | 54 | 0.050 |
Why?
|
Evoked Potentials, Auditory, Brain Stem | 2 | 2015 | 17 | 0.050 |
Why?
|
Neutralization Tests | 4 | 1991 | 77 | 0.050 |
Why?
|
Predictive Value of Tests | 3 | 2012 | 1673 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 1992 | 172 | 0.050 |
Why?
|
Cohort Studies | 2 | 2020 | 2767 | 0.050 |
Why?
|
Rats | 1 | 2006 | 3990 | 0.050 |
Why?
|
Capsid | 3 | 1992 | 34 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 1992 | 176 | 0.050 |
Why?
|
Mice, Inbred C57BL | 2 | 2015 | 3092 | 0.050 |
Why?
|
Viral Core Proteins | 3 | 1991 | 27 | 0.050 |
Why?
|
Rotavirus | 1 | 1999 | 11 | 0.040 |
Why?
|
North America | 2 | 2014 | 180 | 0.040 |
Why?
|
Biological Availability | 2 | 2014 | 92 | 0.040 |
Why?
|
Phenotype | 4 | 2019 | 2378 | 0.040 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2006 | 878 | 0.040 |
Why?
|
Arbovirus Infections | 1 | 1999 | 2 | 0.040 |
Why?
|
Body Weight | 2 | 2014 | 459 | 0.040 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 1999 | 22 | 0.040 |
Why?
|
Microscopy, Electron | 4 | 1996 | 503 | 0.040 |
Why?
|
Rabies | 1 | 1999 | 7 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 2 | 1998 | 196 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2001 | 912 | 0.040 |
Why?
|
Ganglia | 3 | 1990 | 14 | 0.040 |
Why?
|
Biotransformation | 2 | 2014 | 50 | 0.040 |
Why?
|
Retroviridae Infections | 1 | 1999 | 48 | 0.040 |
Why?
|
Antibodies, Neutralizing | 1 | 2019 | 112 | 0.040 |
Why?
|
Medical History Taking | 2 | 2005 | 80 | 0.040 |
Why?
|
Vinyl Chloride | 1 | 1998 | 1 | 0.040 |
Why?
|
Radioimmunoassay | 3 | 1994 | 155 | 0.040 |
Why?
|
Binding, Competitive | 2 | 1989 | 145 | 0.040 |
Why?
|
Pneumonia | 3 | 1987 | 179 | 0.040 |
Why?
|
Carcinogens | 1 | 1998 | 108 | 0.040 |
Why?
|
Activities of Daily Living | 1 | 1999 | 204 | 0.040 |
Why?
|
Urine | 2 | 1997 | 90 | 0.040 |
Why?
|
Reverse Transcriptase Inhibitors | 2 | 1995 | 23 | 0.040 |
Why?
|
Interleukin-4 | 1 | 1998 | 127 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 1997 | 73 | 0.040 |
Why?
|
Respirovirus Infections | 2 | 1987 | 12 | 0.040 |
Why?
|
Liver Transplantation | 1 | 2005 | 1268 | 0.040 |
Why?
|
Papillomaviridae | 1 | 1998 | 153 | 0.040 |
Why?
|
Platelet Count | 1 | 1997 | 92 | 0.040 |
Why?
|
Interleukin-10 | 1 | 1998 | 149 | 0.040 |
Why?
|
Bilirubin | 1 | 1997 | 125 | 0.040 |
Why?
|
Occupational Exposure | 1 | 1998 | 80 | 0.040 |
Why?
|
Opportunistic Infections | 2 | 2008 | 59 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2014 | 1019 | 0.040 |
Why?
|
Cost of Illness | 1 | 1997 | 150 | 0.040 |
Why?
|
Occupational Diseases | 2 | 1998 | 55 | 0.040 |
Why?
|
Astrocytes | 1 | 1997 | 139 | 0.040 |
Why?
|
Immunosorbent Techniques | 2 | 1986 | 13 | 0.040 |
Why?
|
Probability | 2 | 2003 | 355 | 0.040 |
Why?
|
Lymphocyte Activation | 4 | 1989 | 728 | 0.040 |
Why?
|
Models, Theoretical | 1 | 1999 | 482 | 0.040 |
Why?
|
Retroviridae | 1 | 1996 | 79 | 0.040 |
Why?
|
Recombination, Genetic | 3 | 2011 | 439 | 0.040 |
Why?
|
International Cooperation | 1 | 1996 | 127 | 0.040 |
Why?
|
Multiple Sclerosis | 1 | 1998 | 262 | 0.040 |
Why?
|
Survival Rate | 2 | 1999 | 1863 | 0.030 |
Why?
|
Mutagenesis, Insertional | 1 | 1996 | 111 | 0.030 |
Why?
|
Professional Staff Committees | 1 | 1995 | 7 | 0.030 |
Why?
|
Cell Membrane | 2 | 1991 | 666 | 0.030 |
Why?
|
Hospitals, Special | 1 | 1975 | 7 | 0.030 |
Why?
|
Herpesvirus 4, Human | 2 | 1987 | 114 | 0.030 |
Why?
|
Injections | 2 | 2013 | 109 | 0.030 |
Why?
|
Lung Diseases | 1 | 1998 | 263 | 0.030 |
Why?
|
Myelitis, Transverse | 1 | 1995 | 10 | 0.030 |
Why?
|
Morphogenesis | 2 | 1989 | 192 | 0.030 |
Why?
|
Interferon-alpha | 1 | 1996 | 233 | 0.030 |
Why?
|
Antigens, Surface | 4 | 1990 | 101 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 1999 | 484 | 0.030 |
Why?
|
Oropharynx | 1 | 2015 | 15 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 1998 | 381 | 0.030 |
Why?
|
Half-Life | 3 | 2005 | 96 | 0.030 |
Why?
|
Advisory Committees | 1 | 1995 | 90 | 0.030 |
Why?
|
Audiometry | 1 | 2015 | 16 | 0.030 |
Why?
|
Gene Deletion | 1 | 1996 | 329 | 0.030 |
Why?
|
Adenoviridae | 1 | 1996 | 345 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 2007 | 315 | 0.030 |
Why?
|
Encephalitis, Varicella Zoster | 1 | 2015 | 6 | 0.030 |
Why?
|
Drug Resistance | 1 | 1996 | 256 | 0.030 |
Why?
|
Surveys and Questionnaires | 3 | 2010 | 2501 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 1995 | 122 | 0.030 |
Why?
|
Papillomavirus Infections | 1 | 1998 | 239 | 0.030 |
Why?
|
Databases, Factual | 1 | 1998 | 814 | 0.030 |
Why?
|
In Vitro Techniques | 2 | 1995 | 989 | 0.030 |
Why?
|
Nectins | 1 | 2014 | 9 | 0.030 |
Why?
|
Gene Silencing | 1 | 2015 | 172 | 0.030 |
Why?
|
Pneumonia, Pneumocystis | 2 | 1987 | 18 | 0.030 |
Why?
|
California | 1 | 2015 | 138 | 0.030 |
Why?
|
Drug Approval | 1 | 2015 | 62 | 0.030 |
Why?
|
Creutzfeldt-Jakob Syndrome | 2 | 1986 | 25 | 0.030 |
Why?
|
Cricetulus | 1 | 2014 | 126 | 0.030 |
Why?
|
DNA Primers | 1 | 1995 | 543 | 0.030 |
Why?
|
Carboxylic Acids | 1 | 2014 | 17 | 0.030 |
Why?
|
Drug Administration Routes | 1 | 2014 | 19 | 0.030 |
Why?
|
Staphylococcal Protein A | 1 | 1994 | 38 | 0.030 |
Why?
|
Indazoles | 1 | 2014 | 68 | 0.030 |
Why?
|
Rectum | 1 | 2015 | 146 | 0.030 |
Why?
|
Cell Survival | 1 | 1996 | 969 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 1996 | 2705 | 0.030 |
Why?
|
Hepatitis | 2 | 2005 | 35 | 0.030 |
Why?
|
Mice, Nude | 3 | 2002 | 790 | 0.030 |
Why?
|
Genotype | 1 | 2019 | 1851 | 0.030 |
Why?
|
Benzoxazoles | 1 | 1993 | 4 | 0.030 |
Why?
|
Radiography | 2 | 2014 | 813 | 0.030 |
Why?
|
Keratoconjunctivitis | 2 | 1984 | 5 | 0.030 |
Why?
|
Mice, Inbred A | 2 | 2006 | 23 | 0.030 |
Why?
|
Orthopedics | 1 | 1975 | 124 | 0.030 |
Why?
|
Peptides | 2 | 1988 | 639 | 0.030 |
Why?
|
Fibroblasts | 4 | 1990 | 729 | 0.030 |
Why?
|
Diabetes Insipidus | 1 | 1993 | 17 | 0.030 |
Why?
|
Immunoglobulin M | 2 | 1988 | 154 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2015 | 547 | 0.030 |
Why?
|
Pyridones | 1 | 1993 | 51 | 0.030 |
Why?
|
Basidiomycota | 1 | 1993 | 10 | 0.030 |
Why?
|
Tuberculosis | 1 | 2015 | 110 | 0.030 |
Why?
|
Immunization | 2 | 2007 | 158 | 0.030 |
Why?
|
Solubility | 1 | 2013 | 177 | 0.030 |
Why?
|
Creatinine | 2 | 2003 | 338 | 0.030 |
Why?
|
Ganglia, Spinal | 1 | 1993 | 72 | 0.030 |
Why?
|
Cognition Disorders | 1 | 2015 | 236 | 0.030 |
Why?
|
Meningitis, Cryptococcal | 1 | 1992 | 2 | 0.030 |
Why?
|
Linear Models | 1 | 2014 | 421 | 0.030 |
Why?
|
Gonorrhea | 1 | 2012 | 18 | 0.030 |
Why?
|
Nasal Cavity | 1 | 1993 | 91 | 0.030 |
Why?
|
Trifluridine | 2 | 1985 | 6 | 0.030 |
Why?
|
Infant, Premature, Diseases | 3 | 2001 | 78 | 0.030 |
Why?
|
Syphilis | 1 | 2012 | 27 | 0.030 |
Why?
|
Computer Simulation | 2 | 2014 | 1078 | 0.030 |
Why?
|
Genital Diseases, Female | 3 | 1985 | 24 | 0.030 |
Why?
|
Infusions, Parenteral | 2 | 2001 | 50 | 0.030 |
Why?
|
HLA-DR Antigens | 2 | 1989 | 61 | 0.030 |
Why?
|
Toxoplasmosis | 1 | 1992 | 64 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1999 | 1076 | 0.030 |
Why?
|
Vagina | 1 | 1993 | 161 | 0.030 |
Why?
|
Virus Cultivation | 2 | 2006 | 20 | 0.030 |
Why?
|
Macaca | 1 | 1992 | 87 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 1999 | 1169 | 0.030 |
Why?
|
Chick Embryo | 1 | 1992 | 229 | 0.030 |
Why?
|
Consensus | 1 | 2013 | 335 | 0.030 |
Why?
|
Antibody Formation | 1 | 1992 | 171 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2015 | 669 | 0.020 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 1991 | 27 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2015 | 1924 | 0.020 |
Why?
|
Viral Plaque Assay | 1 | 1990 | 19 | 0.020 |
Why?
|
Lung | 2 | 2015 | 1170 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2007 | 559 | 0.020 |
Why?
|
Seroepidemiologic Studies | 1 | 2010 | 55 | 0.020 |
Why?
|
Infusion Pumps | 1 | 1990 | 25 | 0.020 |
Why?
|
Blood Chemical Analysis | 1 | 1990 | 42 | 0.020 |
Why?
|
Heterosexuality | 1 | 2010 | 17 | 0.020 |
Why?
|
Cytotoxicity Tests, Immunologic | 2 | 1987 | 44 | 0.020 |
Why?
|
Zidovudine | 3 | 1995 | 16 | 0.020 |
Why?
|
Herpesvirus 8, Human | 1 | 2009 | 11 | 0.020 |
Why?
|
Protein Binding | 1 | 2013 | 1456 | 0.020 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2009 | 68 | 0.020 |
Why?
|
Age Distribution | 1 | 2010 | 204 | 0.020 |
Why?
|
Pyrimethamine | 2 | 1995 | 21 | 0.020 |
Why?
|
Intensive Care Units | 1 | 1992 | 373 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 860 | 0.020 |
Why?
|
Inclusion Bodies, Viral | 2 | 1985 | 9 | 0.020 |
Why?
|
Molecular Structure | 1 | 2009 | 287 | 0.020 |
Why?
|
Health Policy | 1 | 2010 | 180 | 0.020 |
Why?
|
Immunoglobulin gamma-Chains | 1 | 1988 | 14 | 0.020 |
Why?
|
Methisazone | 2 | 1978 | 2 | 0.020 |
Why?
|
Amantadine | 2 | 1978 | 18 | 0.020 |
Why?
|
Sacroiliac Joint | 1 | 1988 | 7 | 0.020 |
Why?
|
Flucytosine | 1 | 1988 | 11 | 0.020 |
Why?
|
Amphotericin B | 1 | 1988 | 34 | 0.020 |
Why?
|
Ilium | 1 | 1988 | 18 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 1990 | 502 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2009 | 425 | 0.020 |
Why?
|
Pediatrics | 1 | 2012 | 344 | 0.020 |
Why?
|
Evaluation Studies as Topic | 3 | 1994 | 274 | 0.020 |
Why?
|
Pharmacokinetics | 1 | 1987 | 12 | 0.020 |
Why?
|
Hepatitis D | 1 | 1987 | 6 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 1999 | 1721 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 1990 | 1074 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 1987 | 295 | 0.020 |
Why?
|
Anti-Infective Agents, Local | 1 | 2007 | 23 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2008 | 183 | 0.020 |
Why?
|
Immunologic Techniques | 1 | 1987 | 27 | 0.020 |
Why?
|
Aerosols | 1 | 2006 | 44 | 0.020 |
Why?
|
Epithelium | 1 | 1988 | 319 | 0.020 |
Why?
|
Mice, Inbred CBA | 1 | 2006 | 52 | 0.020 |
Why?
|
Nucleosides | 2 | 1979 | 22 | 0.020 |
Why?
|
Cytarabine | 2 | 1978 | 218 | 0.020 |
Why?
|
Antibiotic Prophylaxis | 1 | 2007 | 71 | 0.020 |
Why?
|
Sex Factors | 1 | 1990 | 1054 | 0.020 |
Why?
|
Postoperative Complications | 3 | 1984 | 2207 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2007 | 103 | 0.020 |
Why?
|
Immunoenzyme Techniques | 2 | 1984 | 303 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 1987 | 307 | 0.020 |
Why?
|
Family Practice | 1 | 2007 | 84 | 0.020 |
Why?
|
Genes | 1 | 1987 | 305 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2007 | 131 | 0.020 |
Why?
|
Myelitis | 1 | 1986 | 2 | 0.020 |
Why?
|
Nuclear Envelope | 1 | 1986 | 36 | 0.020 |
Why?
|
Hemiplegia | 1 | 1986 | 15 | 0.020 |
Why?
|
Meningitis, Aseptic | 1 | 1986 | 8 | 0.020 |
Why?
|
Ethics Committees, Research | 1 | 2006 | 33 | 0.020 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 1986 | 13 | 0.020 |
Why?
|
Virion | 1 | 1986 | 59 | 0.020 |
Why?
|
Antineoplastic Agents | 3 | 2005 | 2360 | 0.020 |
Why?
|
Cerebellar Ataxia | 1 | 1986 | 20 | 0.020 |
Why?
|
Phylogeny | 1 | 2011 | 1137 | 0.020 |
Why?
|
Olfactory Bulb | 1 | 1986 | 40 | 0.020 |
Why?
|
Immunity | 1 | 1987 | 136 | 0.020 |
Why?
|
Maternal-Fetal Exchange | 1 | 1985 | 76 | 0.020 |
Why?
|
Graft Survival | 2 | 1979 | 884 | 0.020 |
Why?
|
Erythema | 1 | 1985 | 27 | 0.020 |
Why?
|
Metabolic Clearance Rate | 1 | 1985 | 121 | 0.020 |
Why?
|
Self Disclosure | 1 | 2005 | 31 | 0.020 |
Why?
|
Anemia, Aplastic | 1 | 1985 | 30 | 0.020 |
Why?
|
Epitopes | 1 | 1986 | 255 | 0.020 |
Why?
|
Golgi Apparatus | 1 | 1986 | 117 | 0.020 |
Why?
|
Frontal Lobe | 1 | 1986 | 130 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2008 | 1313 | 0.020 |
Why?
|
Lymphocytes | 1 | 1987 | 464 | 0.020 |
Why?
|
Brain Diseases | 2 | 1985 | 180 | 0.020 |
Why?
|
Syndrome | 1 | 1986 | 446 | 0.020 |
Why?
|
Neurocognitive Disorders | 1 | 1984 | 13 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2006 | 102 | 0.020 |
Why?
|
Fluorouracil | 1 | 2006 | 556 | 0.020 |
Why?
|
Aphasia | 1 | 1984 | 14 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2005 | 158 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2006 | 269 | 0.020 |
Why?
|
Endoplasmic Reticulum | 1 | 1986 | 250 | 0.020 |
Why?
|
Cesarean Section | 1 | 1985 | 137 | 0.020 |
Why?
|
Plasmids | 1 | 2005 | 287 | 0.020 |
Why?
|
Postoperative Period | 1 | 2005 | 303 | 0.020 |
Why?
|
Fibrosis | 1 | 2005 | 203 | 0.020 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2005 | 203 | 0.020 |
Why?
|
Chemistry | 1 | 1983 | 54 | 0.010 |
Why?
|
Chemical Phenomena | 1 | 1983 | 72 | 0.010 |
Why?
|
Hyperbilirubinemia | 1 | 2003 | 20 | 0.010 |
Why?
|
Antilymphocyte Serum | 2 | 1980 | 71 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2009 | 1578 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2005 | 679 | 0.010 |
Why?
|
DNA Replication | 1 | 1984 | 164 | 0.010 |
Why?
|
Defective Viruses | 1 | 2002 | 12 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 1984 | 286 | 0.010 |
Why?
|
Liver | 2 | 2005 | 1230 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 1987 | 1621 | 0.010 |
Why?
|
False Negative Reactions | 1 | 1982 | 63 | 0.010 |
Why?
|
Schizophrenia | 1 | 1985 | 464 | 0.010 |
Why?
|
Rubella | 1 | 1981 | 3 | 0.010 |
Why?
|
Gene Transfer Techniques | 1 | 2002 | 152 | 0.010 |
Why?
|
Electroencephalography | 2 | 2001 | 709 | 0.010 |
Why?
|
Mycoplasmatales Infections | 1 | 1981 | 1 | 0.010 |
Why?
|
Lymphoproliferative Disorders | 1 | 1982 | 107 | 0.010 |
Why?
|
Blood Platelets | 1 | 1982 | 149 | 0.010 |
Why?
|
Sulfadiazine | 1 | 1981 | 24 | 0.010 |
Why?
|
Calcinosis | 1 | 2003 | 224 | 0.010 |
Why?
|
Neurologic Examination | 1 | 1982 | 118 | 0.010 |
Why?
|
Leukocytes | 1 | 1982 | 202 | 0.010 |
Why?
|
Cytokines | 1 | 2005 | 776 | 0.010 |
Why?
|
Injections, Intramuscular | 1 | 1980 | 62 | 0.010 |
Why?
|
Lymphoma | 1 | 1982 | 262 | 0.010 |
Why?
|
Encephalitis Virus, Western Equine | 1 | 1980 | 1 | 0.010 |
Why?
|
Deamination | 1 | 1980 | 6 | 0.010 |
Why?
|
Eye Diseases | 1 | 1980 | 53 | 0.010 |
Why?
|
Biological Therapy | 1 | 2000 | 45 | 0.010 |
Why?
|
Models, Genetic | 1 | 2005 | 926 | 0.010 |
Why?
|
Kidney Diseases | 1 | 1983 | 418 | 0.010 |
Why?
|
Injections, Intralesional | 1 | 1999 | 22 | 0.010 |
Why?
|
X-Rays | 1 | 1999 | 130 | 0.010 |
Why?
|
Contraindications | 1 | 1999 | 72 | 0.010 |
Why?
|
Ophthalmologic Surgical Procedures | 1 | 1999 | 25 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 1983 | 584 | 0.010 |
Why?
|
Genes, p53 | 1 | 1999 | 109 | 0.010 |
Why?
|
Serologic Tests | 1 | 1978 | 41 | 0.010 |
Why?
|
Radiation Tolerance | 1 | 1999 | 168 | 0.010 |
Why?
|
Soft Tissue Neoplasms | 1 | 1999 | 127 | 0.010 |
Why?
|
Wound Healing | 1 | 1980 | 344 | 0.010 |
Why?
|
Hemangiosarcoma | 1 | 1998 | 17 | 0.010 |
Why?
|
Heart Transplantation | 1 | 1984 | 705 | 0.010 |
Why?
|
France | 1 | 1998 | 47 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 1985 | 2601 | 0.010 |
Why?
|
Molecular Epidemiology | 1 | 1998 | 53 | 0.010 |
Why?
|
Antibodies, Neoplasm | 1 | 1998 | 84 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2002 | 1135 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2001 | 469 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 1991 | 2062 | 0.010 |
Why?
|
Nucleocapsid | 1 | 1996 | 3 | 0.010 |
Why?
|
Uterine Cervical Diseases | 1 | 1976 | 8 | 0.010 |
Why?
|
Transplantation, Homologous | 4 | 1979 | 996 | 0.010 |
Why?
|
Phytohemagglutinins | 2 | 1990 | 22 | 0.010 |
Why?
|
Population | 1 | 1996 | 35 | 0.010 |
Why?
|
3T3 Cells | 1 | 1996 | 94 | 0.010 |
Why?
|
Phototherapy | 1 | 1976 | 35 | 0.010 |
Why?
|
Zalcitabine | 1 | 1995 | 2 | 0.010 |
Why?
|
Didanosine | 1 | 1995 | 2 | 0.010 |
Why?
|
Toxoplasmosis, Cerebral | 1 | 1995 | 6 | 0.010 |
Why?
|
Immunoglobulin A | 1 | 1976 | 80 | 0.010 |
Why?
|
London | 1 | 1975 | 16 | 0.010 |
Why?
|
Federal Government | 1 | 1995 | 29 | 0.010 |
Why?
|
Organizational Objectives | 1 | 1995 | 27 | 0.010 |
Why?
|
Sepsis | 1 | 1999 | 306 | 0.010 |
Why?
|
Confidentiality | 1 | 1995 | 78 | 0.010 |
Why?
|
Pemphigoid Gestationis | 1 | 1975 | 1 | 0.010 |
Why?
|
Photochemotherapy | 1 | 1976 | 97 | 0.010 |
Why?
|
Ureaplasma | 2 | 1987 | 4 | 0.010 |
Why?
|
Cadaver | 3 | 1980 | 185 | 0.010 |
Why?
|
Cerebellum | 1 | 1976 | 247 | 0.010 |
Why?
|
HIV Reverse Transcriptase | 1 | 1993 | 14 | 0.010 |
Why?
|
Hospitalization | 1 | 1999 | 849 | 0.010 |
Why?
|
Guinea Pigs | 1 | 1993 | 171 | 0.010 |
Why?
|
Adsorption | 1 | 1993 | 54 | 0.010 |
Why?
|
Culture Media | 1 | 1993 | 147 | 0.010 |
Why?
|
Hospital Bed Capacity, 500 and over | 1 | 1992 | 5 | 0.010 |
Why?
|
Iowa | 1 | 1992 | 35 | 0.010 |
Why?
|
Personnel, Hospital | 1 | 1992 | 30 | 0.010 |
Why?
|
Superinfection | 1 | 1992 | 3 | 0.010 |
Why?
|
Family Health | 1 | 1992 | 162 | 0.010 |
Why?
|
Hospitals, University | 1 | 1992 | 194 | 0.010 |
Why?
|
Baculoviridae | 1 | 1991 | 34 | 0.010 |
Why?
|
HIV Antigens | 1 | 1991 | 4 | 0.010 |
Why?
|
HIV Core Protein p24 | 1 | 1991 | 7 | 0.010 |
Why?
|
HIV Antibodies | 1 | 1991 | 25 | 0.010 |
Why?
|
Cluster Analysis | 1 | 1992 | 369 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 1976 | 724 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 1998 | 736 | 0.010 |
Why?
|
Viral Regulatory and Accessory Proteins | 1 | 1990 | 23 | 0.010 |
Why?
|
Immunoglobulin Light Chains | 1 | 1991 | 86 | 0.010 |
Why?
|
Thymidine Kinase | 1 | 1990 | 30 | 0.010 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 1991 | 131 | 0.010 |
Why?
|
Aotus trivirgatus | 1 | 1990 | 4 | 0.010 |
Why?
|
Immunoglobulin Variable Region | 1 | 1991 | 109 | 0.010 |
Why?
|
Codon | 1 | 1990 | 124 | 0.010 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1990 | 135 | 0.010 |
Why?
|
Family | 1 | 1992 | 311 | 0.010 |
Why?
|
Chromosome Deletion | 1 | 1990 | 229 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 1990 | 154 | 0.010 |
Why?
|
Biomarkers, Tumor | 1 | 1998 | 1464 | 0.010 |
Why?
|
Clone Cells | 1 | 1990 | 213 | 0.010 |
Why?
|
Transfection | 1 | 1990 | 896 | 0.010 |
Why?
|
Anus Neoplasms | 1 | 1988 | 30 | 0.000 |
Why?
|
Drug Tolerance | 1 | 1987 | 63 | 0.000 |
Why?
|
Chlamydia trachomatis | 1 | 1987 | 14 | 0.000 |
Why?
|
Saliva | 2 | 1980 | 122 | 0.000 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 1987 | 132 | 0.000 |
Why?
|
Monocytes | 1 | 1987 | 214 | 0.000 |
Why?
|
Protein Processing, Post-Translational | 1 | 1987 | 371 | 0.000 |
Why?
|
Arabinose | 2 | 1974 | 2 | 0.000 |
Why?
|
Nucleic Acid Hybridization | 1 | 1984 | 245 | 0.000 |
Why?
|
Cloning, Molecular | 1 | 1984 | 646 | 0.000 |
Why?
|
Autopsy | 1 | 1981 | 116 | 0.000 |
Why?
|
Leukopenia | 1 | 1980 | 65 | 0.000 |
Why?
|
Immune Adherence Reaction | 1 | 1979 | 4 | 0.000 |
Why?
|
Complement Fixation Tests | 1 | 1979 | 5 | 0.000 |
Why?
|
Azathioprine | 1 | 1979 | 125 | 0.000 |
Why?
|
Host vs Graft Reaction | 1 | 1978 | 3 | 0.000 |
Why?
|
Mononuclear Phagocyte System | 1 | 1976 | 2 | 0.000 |
Why?
|
Tissue Donors | 1 | 1978 | 463 | 0.000 |
Why?
|
Delivery, Obstetric | 1 | 1975 | 112 | 0.000 |
Why?
|
Infectious Mononucleosis | 1 | 1974 | 6 | 0.000 |
Why?
|
Pharynx | 1 | 1974 | 45 | 0.000 |
Why?
|
Graft Rejection | 1 | 1980 | 1065 | 0.000 |
Why?
|
Adenine Nucleotides | 1 | 1973 | 63 | 0.000 |
Why?
|
Adenine | 1 | 1973 | 85 | 0.000 |
Why?
|
Immunosuppressive Agents | 1 | 1978 | 977 | 0.000 |
Why?
|
Pilot Projects | 1 | 1975 | 839 | 0.000 |
Why?
|